MedTrace Logo

Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder

NCT06651541 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-11-17

No results posted yet for this study

Summary

Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder

Conditions

  • Female Sexual Arousal Disorder
  • Female Sexual Dysfunction (FSD)

Interventions

DRUG

BZ371A (0.5 ml)

Formulation with the active ingredient

DRUG

Placebo (0.5 ml)

Formulation without the active ingredient

DRUG

Placebo (1.0 ml)

Formulation without the active ingredient

DRUG

BZ371A (1.0 ml)

Formulation with the active ingredient

Sponsors & Collaborators

  • Biozeus Biopharmaceutical S.A.

    lead INDUSTRY

Principal Investigators

  • Fabiene Vale, MD PhD · Hospital das Clínicas - UFMG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-06-30
Completion
2027-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06651541 on ClinicalTrials.gov